ERA: Distributed Ledger Technologies, Cryptoassets and Security Tokens: Regulatory Trends
Section
Event Description
Objective
The seminar will analyse the existing and proposed regulations applicable to cryptoassets, security tokens, virtual currencies and their underlying technologies.
Key Topics
- Impact of distributed ledger technologies on financial services
- Regulating distributed ledger technologies, cryptoassets, security tokens and virtual currencies at international, EU and national levels
- The perspective of central banks on virtual currencies
- The risks of buying virtual currencies: a view from the regulators
- Tackling the illicit use of virtual currencies in the EU
Please click here for
further information
Language: English
Organisers: Florence Hartmann-Vareilles (ERA) and Dr. Christopher P. Buttigieg (University of Malta)
Event number: 219D118
Speakers
Patrick Armstrong, Senior Risk Analysis Officer, European Securities and Markets Authority (ESMA), Paris
Christopher Buttigieg, Head, Securities and Markets Supervision Unit, Malta Financial Services Authority; Lecturer, University of Malta
Maria Teresa Chimienti, Market Infrastructure Expert, European Central Bank, Frankfurt
Joshua Ellul, Chairman, Malta Digital Innovation Authority; Director, Center for Distributed Ledger Technologies, University of Malta
Oliver Fußwinkel, Head of Section, Innovations in Financial Technology, German Federal Financial Supervisory Authority (BaFin), Bonn
Loretta Joseph, Advisor, OECD, Paris
Marcel Lötscher, Head of Securities and Markets Division, Financial Market Authority (FMA), Liechtenstein
Rick McDonell, Executive Director, Association of Certified Anti-Money Laundering Specialists (ACAMS), Paris
Sorin Moisa, Member of the European Parliament, Brussels/Strasbourg
Jobs
EURACTIV News
- EU leaders meet at a “summit of rural anger”
- Compromises on the Pharma Package provide balance, say MEPs ahead of ENVI vote [Advocacy Lab Content]
- Bulgaria tries fighting corruption with mobile access to personal health files [Advocacy Lab Content]
- EHDS is not just an agreement; it’s a promise to patients and researchers, says Vandenbroucke [Advocacy Lab Content]
- Reducing regulatory data protection isn’t a successful strategy, says Roche Netherlands GM [Advocacy Lab Content]